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Abstract
Background: Developmental periods in early life may be particularly vulnerable to impacts
of environmental exposures. Human research on this topic has generally focused on single
exposure-health effect relationships. The “exposome” concept encompasses the totality of
exposures from conception onwards, complementing the genome. 
Objectives: The Human Early-Life Exposome (HELIX) project is a new collaborative
research project that aims to implement novel exposure assessment and biomarker methods to 
characterise early-life exposure to multiple environmental factors and associate these with 
omics biomarkers and child health outcomes, thus characterizing the “Early-Life Exposome”.
Here we describe the general design of the project.
Methods: In six existing birth cohort studies in Europe, HELIX will estimate prenatal and 
postnatal exposure to a broad range of chemical and physical exposures. Exposure models
will be developed for the full cohorts totalling 32,000 mother-child pairs and biomarkers will
be measured in a subset of 1,200. Nested repeat-sampling panel studies (N = 150) will collect
data on biomarker variability, use smartphones to assess mobility and physical activity, and
perform personal exposure monitoring. Omics techniques will determine molecular profiles
(metabolome, proteome, transcriptome, epigenome) associated with exposures. Statistical
methods for multiple exposures will provide exposure-response estimates for fetal and child 
growth, obesity, neurodevelopment, and respiratory outcomes. A health impact assessment
exercise will evaluate risks and benefits of combined exposures.
Conclusions: HELIX is one of the first attempts to describe the early-life exposome of
European populations and unravel its relation to omics markers and health in childhood. As
proof of concept, it will form an important first step towards the life-course exposome.
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Introduction 
Environmental hazards such as ambient air pollution, environmental tobacco smoke, noise, 
pesticides and radiations may lead to serious, chronic pathologies. The foetus and infant are 
particularly vulnerable to such potential hazards (Barouki et al. 2012; Gluckman and Hanson 
2004; Hines et al. 2010). Environmental exposures, preconceptionally, in utero and during 
early life may permanently change the body’s structure, physiology, and metabolism 
(Gluckman and Hanson 2004). Such changes can promote disease long after the 
environmental exposure has occurred, including across generations. Environmental exposures 
during foetal or early life have been associated with adverse foetal growth and with 
developmental neurotoxic, immunotoxic and obesogenic effects in children, but for many of 
these associations evidence has been classified as limited or inadequate (e.g. Bellinger 2013; 
Gascon et al. 2013a; La Merrill and Birnbaum 2011; Wigle et al. 2008). Neurodevelopmental 
disabilities, obesity and asthma are common and highly complex chronic pathologies and it is 
hypothesised that improved understanding of how simultaneous environmental risk factors 
interact between themselves, with individual characteristics (e.g. genetics), and with 
epigenetics, can help elucidate their causes (Bousquet et al. 2011; Gallagher et al. 2011; 
Trasande et al. 2009; Van den Bergh 2011). Up to now, the field of environment and child 
health has almost uniquely focused on single exposure-health effect relationships; there is no 
global view of how various types of exposures co-exist and jointly impact on health.  
The exposome 
The “exposome” concept was first proposed by Wild (2005) to encompass the totality of 
human environmental (i.e. non-genetic) exposures from conception onwards, complementing 
the genome; it was developed “to draw attention to the critical need for more complete 
environmental exposure data in epidemiological studies” (Wild 2012). In this concept, the 
exposome contains several overlapping domains of non-genetic factors contributing to 
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disease risk, including a general external domain (social, societal, urban environment, climate
factors), a specific external domain (specific contaminants, lifestyle factors, tobacco, 
occupation), and an internal environment (metabolism, gut microflora, inflammation, 
oxidative stress) (Wild 2012). The exposome calls for improvement of often uncertain 
exposure data, for integration of data on biological mechanisms, and for a more holistic
exposure approach in epidemiological studies. Furthermore, it has been proposed that the
exposome may serve an important purpose in characterising not only the complex mixtures of
already identified exposures, but in addition, through its untargeted approach and the use of
high-throughput “omics” techniques, relevant exposures that have thus far remained 
unidentified (Rappaport 2011; Rappaport and Smith 2010). There are large challenges in 
developing the exposome concept into a workable approach, including the consideration of
multiple, longitudinal time periods of interest and of temporal variability, the
acknowledgement of exposure uncertainty in an exposome study, the integration of omics
data, and the development of powerful statistical techniques to analyse the associations 
between exposome data and adverse health end points.
The HELIX (Human Early-Life Exposome) project has as its general aim to implement tools
and methods (biomarkers, omics-based approaches, remote sensing and GIS-based spatial
methods, personal exposure devices, statistical tools for combined exposures, and burden of
disease methodologies), to characterise early-life exposure to a wide range of chemical and 
physical environmental factors and associate these with data on major child health outcomes
(growth and obesity, neurodevelopment, respiratory health), thus developing an “Early-Life 
Exposome” approach. The project takes pregnancy and childhood periods (“early life”) as the
starting point for developing the life-course exposome. This paper describes the general
design of HELIX and its main challenges. In this manner, we aim to illustrate how the
exposome concept may be implemented in a feasible epidemiological study design.
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Project Concept, Objectives and Study Populations 
HELIX will develop the early-life exposome approach and database in three overlapping 
steps containing six research areas (Figure 1). A first step will measure the external 
exposome - exposure estimates for a broad range of chemical and physical exposures, a 
second step will measure the internal exposome (molecular signatures) and integrate the 
multiple dimensions of the exposome - multiple exposures, multiple time points, individual 
variability -, and a third step will develop the tools and methods to evaluate the exposome’s 
impact on child health (Figure 1). The project is based in six existing population-based birth 
cohort studies in Europe (Figure 2). Objectives are: 
Step 1: Measuring the external exposome  
-­‐ To obtain estimates of exposure to persistent and non-persistent pollutants in food, 
consumer products, water and indoor air, during pregnancy and in childhood.  
-­‐ To obtain estimates of chemical and physical exposures in the outdoor environment 
during pregnancy and in childhood: ambient air pollution, ambient noise, ultraviolet 
(UV) radiation, temperature, and built environment/green space.   
Step 2: Integrating the external and internal exposome: 
-­‐ To define multiple exposure patterns in the individual and outdoor environment, describe 
their predictors, and describe uncertainties and variability in the exposures assessed. .  
-­‐ To measure molecular signatures associated with environmental exposures through 
analysis of profiles of metabolites, proteins, transcripts, and DNA methylation in 
biological samples from the children in the cohorts. Biological pathway analyses will be 
used to inform analyses of the relationship between multiple exposures and child health. 
6
 
   
  
 
 
         
         
     
            
          
        
        
     
      
        
Step 3: Impact of the early-life exposome on child health 
-­‐ To develop a novel multi-step statistical approach for the analysis of the association of 
patterns of multiple and combined exposures and child health outcomes, using agnostic 
environment-wide association study (EWAS) analysis, structural equation modelling 
(SEM), and Bayesian profile regression.  
-­‐ To provide exposure-response estimates for the association between multiple and 
combined exposures, and child health focusing on foetal and childhood growth and 
obesity, neurodevelopment, and respiratory health.  
-­‐ To estimate the burden of common childhood diseases that may be attributed to multiple 
environmental exposures in Europe.  
-­‐ To strengthen the knowledge base for European policy in the area of child and 
environmental health by engaging with, and effectively disseminating HELIX 
knowledge to, stakeholders including those responsible for risk management and 
mitigation and prevention strategies.  
The birth cohorts
Six existing longitudinal population-based birth cohort studies in Europe form the basis of the
project: BiB (UK) (Wright et al. 2012), EDEN (France) (Drouillet et al. 2009), INMA (Spain) 
(Guxens et al. 2012), KANC (Lithuania) (Grazuleviciene et al. 2009), MoBa (Norway) 
(Magnus et al. 2006), and RHEA (Greece) (Chatzi et al. 2009) (Figure 2). The cohorts were
selected because a) they each have a large amount of existing longitudinal data from early 
pregnancy through childhood, b) they can implement new follow-up examinations of the
children at similar ages (6-9 yrs), old enough for accurate measurement of the phenotypes of
interest for HELIX, and c) they can integrate new questionnaires, biosampling and clinical
examinations in their new follow-ups using common protocols. The cohorts have worked 
together intensively and have pooled data as part of other EC projects (Supplemental
7
 
   
  
 
         
       
 
 
        
       
      
        
      
      
   
           
         
       
         
      
        
     
        
         
           
       
     
     
Material, Previous EU projects contributing data and expertise to HELIX; Larsen PS et al.
2013; Vrijheid et al. 2012). The selection of cohorts followed a strategy to obtain data in 
different regions of Europe.
Study populations
In general, exposure estimates can be obtained in cohort studies for very large numbers of
subjects by exposure models and questionnaires, whereas exposure and omics biomarkers
can, for cost reasons, only be obtained in smaller numbers of subjects. Assessment of
individual exposure variability and validation of exposure models in require very intensive
data collection that is only feasible in an even smaller number of subjects. For these reasons, 
HELIX uses a multi-level study design, drawing on nested study populations for different
levels of data collection (Figure 3):
1) The entire six cohorts of 32,000 mother-child pairs will form the basis of existing data. 
From this study population we will use existing exposure data such as tobacco use, ESCAPE
air pollution land-use regression (LUR) models (Eeftens et al. 2012), water disinfection by-
products (DBPs) exposure models from the HiWate project (Nieuwenhuijsen et al. 2009), 
confounder data, and outcome data. Outdoor exposure estimates (research area 2 below) will
be applied to these entire cohorts. Risk estimates for the effects of combined outdoor 
exposures (the “outdoor exposome”) on child health will be obtained in this study population. 
The harmonisation process of the existing data will build upon protocols and expertise
developed in earlier collaborative EC projects (Bousquet et al 2011, Eeftens et al 2012, 
Larsen et al 2013, Vrijheid et al. 2012 - Supplemental Material, Previous EU projects
contributing data and expertise to HELIX). Outcomes that can be harmonised across cohorts
include birth outcomes; postnatal growth and body mass index (BMI); self reported 
wheezing, doctor diagnosed asthma and measures of lung function; and neurodevelopment
8
 
   
  
 
       
    
    
         
     
       
      
        
       
        
      
         
        
           
     
      
        
               
         
       
           
       
      
       
        
harmonized as five neurodevelopmental constructs (general cognition, language
development, motor abilities, socio-emotional behaviour and attention deficit hyperactivity 
disorder symptomatology) across different age groupings. 
2) A HELIX subcohort of 1,200 mother-child pairs (Figure 3) will be fully characterized for 
the external and internal exposome, including exposure biomarkers during pregnancy and 
childhood, and omics biomarkers during childhood. The impact of the total early-life 
exposome on child health will be characterized in these 1,200 mother-child pairs. The 1,200 
mother-child pairs will be nested within the entire cohorts by selecting 200 pairs from each 
cohort. Eligibility criteria include: a) age between 6 and 9 years, 7-8 if possible; the age range
should be as narrow as possible for comparability of omics analyses and exposure-related 
behaviour; b) stored pregnancy blood and urine samples available and available sample
volume sufficient for the analysis of exposure biomarkers detailed in research area 1; c) 
complete address history available from first to last follow-up point; d) no serious health 
problems that, in the opinion of a local clinician, may affect the performance of the clinical
testing (e.g spirometry) or impact the volunteer's safety (e.g. renal failure, pneumonia). In 
addition, the selection will consider whether data on important covariates (genetic data, diet, 
socio-economic factors) is available. Cohorts with more than the required number of mother-
child pairs that meet these criteria will invite subjects at random from the eligible pool. The
new follow-up examination will include the collection of new biological samples suitable for 
all planned biomarker and omics analyses (research areas 1 and 4 below). The collection of
two urine samples (one before bed-time and one first morning void) will better capture short-
lived biomarker metabolites and provide more stable metabolome coverage than would be
achieved with one spot urine sample. Collected blood samples will be processed into 
appropriate matrices (including whole blood, serum and plasma) and storage mediums (for 
RNA and DNA extraction), and will be rapidly deep frozen under optimized and standardised 
9
 
   
  
 
          
       
        
   
      
   
   
      
      
       
       
      
        
        
    
        
 
           
      
     
           
       
          
          
         
processing procedures. Variables that can impact omics profiles, such as use of drugs, time of
last meal, physical exercise, will be collected. Trained nurses will carry out health 
examinations of the children. Examinations include measurements of weight, height, waist
circumference, skin folds, blood pressure and spirometry, and will follow standard operating 
procedures. Standardized computer-assisted interviews with the mothers will collect
information on exposure sources (smoking, cooking, heating, water consumption), physical
activity, time activity, diet, social factors, stress, and asthma and allergy. 
Neurodevelopmental outcomes will be assessed through a battery of internationally 
standardized, non-linguistic, and culturally blind computer tests (N-BACK (Vuontela et al.
2003), Attention Network Test (Rueda et al. 2004), Trail Making Test (Lezak 2004), Raven
(Raven et al. 1998)). Parents will complete the Conners’ (Conners 1997) and Child 
Behaviour Checklist (CBCL – Achenbach 2000) questionnaire to assess child behavioural
problems. Besides the standardization of procedures and questionnaires, the project will
implement data collection QA/QC through the central training of nurses and field workers -
including training workshops with harmonization and reliability exercises (e.g. for the
skinfold measurements) - and through visits of coordinators to the local cohorts during the
fieldwork to monitor adherence to the standard operating procedures. 
3) Panel studies (Figure 3) will collect data on short-term temporal variability in exposure
biomarkers and omics biomarkers, on individual behaviours (physical activity, mobility, time
activity), and on personal and indoor exposures. A children panel study (Figure 3) will 
include children from the HELIX subcohort (N = 150, 25 from each cohort) and will thus be
based on the same inclusion criteria. An added requirement for the panel study is that
children must be able to wear equipment without destroying it. Invitations will be sent to all
families included in the subcohort, but because of the intensive monitoring involved it is
expected that only the most cooperative families will agree to participate, so randomness
10
 
   
  
 
         
          
        
             
        
            
        
       
        
 
       
          
          
       
        
    
    
         
        
          
            
          
 
cannot be guaranteed; detailed information allowing to discuss if the panel study differs from
the larger groups will be available. A pregnant women panel (Figure 3) will include 150 
pregnant women, 50 from 3 of the regions under study, and these will be volunteer women 
from outside the cohorts; mothers from the cohorts cannot be used for this purpose as their 
pregnancies were several years ago. Criteria for inclusion are: singleton pregnancy, age equal
or above 18 years at the time of start of pregnancy, first visit to be conducted before week 20 
of the pregnancy, and living in the study area covered by the cohort. Study areas will be
defined taking into account the availability of fine-scale air pollution models; as far as
possible they should correspond to the study areas of the original cohorts, or at least cover 
similar areas.
Subjects in the children and pregnant women panel study will be followed for 1 week in 2 
seasons. From these subjects we will collect daily urine samples, first morning and last night
time void, and from the pregnant women an additional midday void if possible. At the end of
each monitoring week, blood samples will be collected following the same procedures as for 
the subcohort. Subjects or their mothers will complete diaries to collect information on meal 
times, cosmetics and medication use and urination frequency for input into the
physiologically based pharmacokinetic (PBPK) models described under research area 1 
below. The subjects will carry smartphones and personal monitors, and indoor air and noise
monitors will be installed in the homes (research area 2 below). Additional QA/QC 
procedures in the panel studies focus on ensuring that the two monitoring periods follow the
same procedures in all cohorts and that blood is collected at approximately the same time of
the day and under the same conditions in both periods and in all cohorts. The latter is
important to reduce variability in the omics analyses.
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4) Health impacts for the larger European population will then be estimated using the
exposure levels and dose-response relations from HELIX (Figure 3), together with dose-
response and threshold estimates from the literature and prevalence data from European 
registries and birth cohorts (Vrijheid et al. 2012). 
Measuring the External Exposome 
Accurate assessment of environmental exposures (reduction of exposure misclassification) 
remains an important outstanding challenge for health risk and impact assessment. In 
developing the exposome concept this challenge is multiplied, because it requires obtaining 
exposure data for many different exposures. Within the external exposome, a distinction can 
be made between largely individually assessed exposures such as environmental tobacco 
smoke (ETS), water contaminants, persistent organic pollutants (POPs), pesticides and 
metals, which are traditionally assessed through questionnaires and/or biomonitoring on an 
individual basis, and exposures in the outdoor environment such as outdoor air pollutants and 
noise, where, so far, the residence is taken for estimation of exposure, ignoring mobility.  
Research Area 1 – Individual Exposures 
Individually assessed exposures can vary on an hourly or daily to yearly basis. Temporal 
variability is particularly high for exposures with a short biological half-life and little 
constancy in the underlying exposure behaviour (e.g. bisphenol A (BPA), phthalates, 
organophosporous pesticides – Bradman et al. 2013; Braun et al. 2011; Philippat et al 2013; 
Preau et al. 2010). For such exposures, intra- compared to inter-individual variability is 
known to be high and only many repeat measurements over time may give improved 
exposure estimates. For more persistent exposures, biomarkers give more long-term exposure 
estimates that are influenced by changes in diet or behaviour, e.g. by breastfeeding patterns. 
Research area 1 will measure exposure biomarkers in the subcohort (N=1,200) in appropriate 
12
 
   
  
 
     
    
    
      
        
         
     
      
     
   
       
         
       
           
      
        
   
      
       
      
          
          
         
         
      
biological samples newly collected from the children and previously collected from mothers
during pregnancy. Biomarkers include POPS - PCBs, dichlorodiphenyldichloroethylene
(DDE), hexachlorobenzene (HCB), polybrominated diphenyl ethers (PBDEs), perfluoroalkyl
substances (PFAS) - in blood samples, non-persistent chemicals - phthalates, phenols, 
organophosphate pesticides - in urine samples, metals in blood, and cotinine as a biomarker 
of ETS exposure (Table 1). Pre- and postnatal questionnaires will collect information on 
water consumption habits, which will be combined with information on concentrations of
DBPs in drinking water from water companies to obtain estimates of exposure to DBPs. 
Questionnaires will also collect information on sources of indoor air pollution including ETS, 
cooking and heating appliances, and ventilation (Table 1). In the panel studies, indoor air 
pollution will be measured to characterise errors when using exposure information from
questionnaires and models. This will be done using passive samplers for nitrogen dioxide
(NO2) and BTEX (benzene, toluene, ethylene, and xylene), and active PM2.5 Cyclone pumps, 
installed in the home. The panel studies will measure daily repeat biomarkers of the non-
persistent chemicals (phthalates, phenols, organophosphate pesticides) in urine (Table 1);
these data will be used to characterise inter and intra-individual variability in these urine
biomarkers, and where possible, correct for the uncertainties in the larger cohort.
One further source of uncertainty in exposure estimates based on biomarker concentrations, is 
their relationship to the internal biologically effective dose (Sobus et al. 2011). The measured 
biomarker concentration cannot always be considered as a steady state concentration (in 
particular for non-persistent chemicals), nor as a surrogate for the internal dose of the target
tissue and has often not been sampled during the entire critical time window (Bartell et al. 
2004; Clewell et al. 2008). Here, modelling the toxicokinetics of the chemical using PBPK
may help the interpretation of the measured biomarker data. PBPK models describe the fate
of chemicals in the body using individual-specific information about the physiology (age, 
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gender, weight) and the biochemistry (enzyme content) of the individual as well as 
information on the individual’s behaviour (breastfeeding, physical activity, diet) (Beaudouin 
et al. 2010). In the context of population (epidemiological) studies, PBPK models can be used 
to simulate exposure during critical time periods in between biomarker measurement points 
(e.g. Gascon et al. 2013b; Lyons et al. 2008; Ulaszewska et al. 2012; Verner et al. 2010). To 
be relevant, this approach requires detailed input data on individual characteristics and 
behaviours to minimize assumptions and uncertainties. HELIX will evaluate the use of PBPK 
modelling to interpret biomarkers of exposure to perfluorinated alkyl substances  
(perfluorooctane sulfonate (PFOS), perfluorooctanoic acid (PFOA), and di-2-ethyl hexyl 
phthalate (DEHP). For the PFAS, we propose to relate the biomarker measurement in the 
child to that in the mother during pregnancy using an exposure scenario that integrates 
maternal-foetal transfers during pregnancy, transfers via breast milk, and diet during 
childhood. For DEHP, repeat biomarkers in the panel studies and information on exposure-
related behaviours and urination times will be used to evaluate the predictable value of 
different numbers of biomarker measurements. 
Research Area 2 – Outdoor Exposures 
For exposures that are traditionally assessed on the basis of residential location, such as 
outdoor air pollutants, noise and the built environment, major improvements in exposure 
assessment and reduction in measurement error can be achieved by collecting information on 
time-space activity, and, in case of air pollution, on how much air a person inhales. 
Knowledge on physical activity, which constitutes a proxy of the inhalation rate (Kawahara et 
al 2011) for example, may be integrated with personal air pollution measurements to estimate 
inhalation dose. New geographic information system (GIS) based exposure assessments 
(Beelen et al. 2013; Eeftens et al. 2012), remote sensing (Dadvand et al. 2012) and 
14
 
   
  
 
          
      
          
    
    
       
    
       
     
        
      
         
            
        
     
     
     
        
  
    
            
   
smartphone technologies (de Nazelle et al. 2013) have made it easier to assess outdoor 
exposures, and to integrate personal mobility and physical activity data.
Research area 2 will construct a GIS environment for the six cohorts, and will assign 
exposure estimates for air pollutants, noise, UV radiation, temperature, built
environment/green spaces. The estimates will build on existing land-use regression air 
pollution maps (Beelen et al. 2013; Eeftens et al. 2012), noise maps, UV index and 
METEOSAT data, green space estimates, and walkability, building density, bike lane map 
information for the built environment (Table 2). Data from existing regulatory monitors and 
remote sensing data from, for example, the Tropospheric Emission Monitoring Internet
Service (http://www.temis.nl/) will be used to inform ambient spatial exposure models. The
aim is to obtain average exposure estimates for the pregnancy period, and during childhood 
for different time periods, including one day, one week, one month, and one year before the
outcome and omics assessment. Smart phones will be worn by the participants in the panel
studies to provide geolocation data every second and the metabolic equivalent of tasks
(METs) every 10 seconds, derived from the in-built accelerometer and GPS and integrated on 
the specially developed ExpoApp. We will then translate these data into activity type (resting, 
cycling, car travel) and derive inhalation rates. The panel study subjects will also wear 
electronic wrist band UV dosimeters (Seckmeyer et al. 2011), PM2.5 active samplers
(DCG4004 sampling pump with GK”.05SH Cyclone inlet, BGI Instruments, USA), and 
MicroAthelometers (AE-51, Envirodata, Spain) for continuous black carbon monitoring
(Table 2). Personal exposure estimates will be used to characterize uncertainties in the spatial
exposure models.
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Integrating the External and Internal Exposome 
Research Area 3 – Integrating Exposures 
Once individual and outdoor exposures have been estimated, research area 3 will use 
analysis-of-variance techniques, incorporating data from both the HELIX subcohort and the 
panel studies, to understand the variance components for each key exposure (for instance 
arising from diet, physical activity, or time of sampling) and describe the uncertainties in 
each of the exposure estimates. Statistical techniques such as factor analysis and latent class 
analysis will be used to create a reduced set of continuous exposure indices based on 
commonly occurring exposures, while individuals that share similar exposure profiles or 
“exposomes” will be defined. We will then determine the influence of variables such as diet, 
socio-economic status, study region and seasonality on these exposure indices or profiles. 
Specific attention will be given to the detection of cohort-specific exposure patterns.  
Research Area 4 - Integrating Molecular Exposure Signatures  
High-throughput molecular biology “omics” techniques (such as metabolomics, proteomics, 
transcriptomics, epigenomics) have important potential for broad and untargeted 
characterisation of the internal exposome (Ellis et al. 2012; Hebels et al. 2013). Here, the 
interest is in the identification of exposure biomarkers and mechanistic pathways. Research 
area 4 will determine molecular signatures associated with environmental exposures through 
the measurement of endogenous and xenobiotic metabolite profiles in blood and urine, 
proteins in plasma, and coding and small non-coding RNAs (including miRNAs) and DNA 
methylation in whole blood. Omics tools will be employed mainly in the subcohort of 1,200 
children with newly collected biosamples at age 6-9 years; the use of new samples ensures 
comparability between techniques and cohorts (Figure 4, Table 3, and Supplemental Material, 
Detailed description of omics techniques to be used in HELIX). The use of a similar time 
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point for all omics techniques also allows integration of the different techniques during data
analysis. Genotyping is available already in most of the cohorts and will be completed where
needed. Two main limitations in epidemiological studies aiming to use omics biomarkers, are
tissue and intra-individual variability. Omics profiles are tissue specific and the tissue of
interest can usually not be obtained (e.g. adipose tissue, brain tissue). The focus of HELIX is
thus on markers in systemic biological samples (blood, urine) to evaluate the use of omics
biomarkers as markers of exposure changes in (larger) epidemiological studies. Omics 
profiles change over time in the same person; a cross-omics paper with three repeat analyses
in 16 subjects over a one month period showed that intra-individual variability for 
metabolomics and transcriptomics was found to be lower than inter-individual variability for 
almost all the biomarkers (Gruden et al. 2012). However, some sets of markers were highly 
variable within the same subject and can thus not directly be used in epidemiological studies. 
Further, longer time periods of one month are likely to give higher intra-individual
variability. HELIX will make some progress towards characterising intra and inter-individual
variability in the metabolomics and transcriptomics markers by analysing repeat biological
samples collected in the panel studies in different seasons.
The omics work will be implemented in three general stages:  
Stage 1) Study design optimization: Biological samples collected in the panel studies (daily 
urine samples, 2 blood samples) will be used to assess detectability of omics markers and the 
likely sources of variability within and between individuals, using small numbers of subjects. 
These results will inform the design and interpretation of stages 2 and 3. 
Stage 2) Omics-exposure associations in the biological samples newly collected in the 
subcohort (N = 1,200): Primary analyses will evaluate three a-priori defined exposures (ETS, 
total POP concentration, and air pollution) and on the specific multiple exposure clusters 
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generated in research area 3. The three exposures have been selected because we have
comparatively good long-term exposure estimates and there is already some data also from
human omics studies (Bollati and Baccarelli 2010; Hou et al. 2011; Hou et al. 2012; Rusiecki
et al. 2008). Power calculations for these analyses are detailed in the Supplemental Material
(Detailed description of omics techniques to be used in HELIX). Secondary analyses will
examine other exposures. Panel study data will evaluate short-term exposure-omics
associations for a range of exposures for which detailed data is collected in the panels: air 
pollution, noise, UV, and non-persistent chemicals.  
Stage 3) Biologically meaningful omics “hits” will be then linked to our main child health 
endpoints, similar to the “meet-in-the middle” approach to biomarker discovery (Chadeau-
Hyam et al. 2011). The child health outcomes will be largely continuous outcome scores
(BMI z-score, cognitive score, lung function). If relevant, reverse causality potential may be
evaluated in blood and urine samples available in some of the cohorts at earlier time points
(Figure 4).
In order to analyse, integrate, and interpret the large amounts of data generated by individual
omics techniques, HELIX will apply a pathway analysis approach. The biomarkers obtained 
from the association analysis, in combination with available libraries of biological pathways
(GO - http://www.geneontology.org/, KEGG - http://www.genome.jp/kegg/, Reactome -
http://www.reactome.org/, Comparative Toxicogenomics Database - http://ctdbase.org/), will
be used to identify biological pathways affected by the exposures. Identification and 
representation of biological-toxicological pathways will be done using software such as
Ingenuity Pathway Analysis - http://www.ingenuity.com/, Cytoscape (Saito et al 2012, and 
Impala (Kamburov et al. 2011). Pathway approaches combining data from different omics
techniques (e.g. metabolomics and transcriptomics) are also starting to be developed to search 
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for common pathways determining sensitivity to pharmaceutical and toxic agents (Cavill et
al. 2011; Jennen et al. 2011; Kamburov et al. 2011); HELIX aims to use similar approaches.
Associating the Exposome with Child Health 
Finally, one of the greatest challenges of the exposome concept lies in the assessment of its
association with health outcomes: how can we integrate multi-dimensional exposome data to 
draw meaningful conclusions about (child) health impacts? In general, environmental health 
studies have considered single exposures or single families of exposure (e.g., atmospheric
pollutants, drinking water pollutants). Notable exceptions of studies that have provided risk 
estimates for multiple exposures include a cross-sectional exposure-wide association study 
(EWAS) of diabetes (Patel et al. 2010; Patel et al. 2013), or a study by Budtz-Jorgensen 
(Budtz-Jorgensen et al. 2010) jointly considering PCBs and mercury. Statistical analyses that
consider many exposure variables simultaneously in a naïve (agnostic) way, such as the
EWAS, strongly increase the risk of observing random associations (false positives) because
of multiple testing, and of underestimating the global effect of the environment. In 
developing statistical tools for the analysis of many exposure factors, important lessons
should be drawn from the achievements but also the limitations (Shi and Weinberg 2011) of
the parallel genome-wide association studies (GWAS) field, particularly regarding the
probably weak efficiency of purely agnostic approaches, the very large sample sizes required,
and the need to use complementary approaches (e.g. pathway analysis) making use of a priori
information. 
Further, the exposome includes evaluation of multiple exposures, omics markers and 
outcomes, each with very different temporal scenarios. A challenge in the development of the
statistical analysis protocols is to takes these complexities into account. For example, spatial
models for the outdoor exposures are constructed for a specific year and can then be
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extrapolated to relevant time periods (days, weeks, months or years) backward or forward in 
time using available monitoring stations data. For persistent pollutants we may assume that
biomarkers give estimates over a relatively long time period whereas for non-persistent
pollutants biomarkers will reflect only very recent exposures; in some cases we may assume a
fairly constant exposure pattern depending on the habits underlying the exposure (e.g. 
cosmetics use, dietary patterns), whereas in other cases exposure variations may be largely 
seasonal (e.g. sunscreens, pesticides). Neurodevelopment, growth and obesity, and asthma
and allergies, are each driven by extremely complex multi-stage developmental processes that
take place prenatally and during the first years of postnatal life. Commonly used statistical
techniques for high dimensional data, such as machine learning, dimension reduction and 
variable selection techniques, need to be adapted to the longitudinal context by 
accommodating issues such as time-varying exposure effects, delayed effects, and effects of
exposure trajectories over time on outcome trajectories (Buck Louis 2012). 
Research Area 5 – Linking the Exposome to Child Health 
Research area 5 aims to develop a multi-step approach that is based on several tools and 
methods and will produce risk estimates for different types of exposure variables:  
1) Many single exposure variables: an agnostic EWAS approach with no a priori information, 
in which all pairs of exposure-outcome associations will be quantified (using classical 
regression models), appropriately controlling for false discovery rate (FDR), as is done in 
GWAS and in the only published EWAS (Patel et al. 2010; Patel et al. 2013); spline and 
other smoothing models (Slama and Werwatz 2005) will then look for possible thresholds 
in dose-response relationships.  
2) Combined exposure variables: a structural equation modelling (SEM) approach (Budtz-
Jorgensen et al. 2010) in which synthetic exposure variables will be built based on 
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previous knowledge summarised by directed acyclic graphs. Several sets of synthetic
exposure variables will be considered, including based on common exposure pathways
(e.g. indoor and outdoor air pollutants), on exposure patterns generated by the project and 
on knowledge of biological pathways. 
3) Groups of subjects sharing a similar exposome: a Bayesian Profile Regression, which aims 
to identify groups of individuals sharing a similar exposome that at the same time show
marked differences according to the health outcome variable of study (Molitor et al. 2010;
Papathomas et al. 2011). This is achieved by fitting model-based clustering to the
exposure data, while allowing the outcome of interest to influence cluster membership. 
This technique was used, for example, to identify as a high risk set for lung cancer a
cluster of subjects characterised by their living close to a main road, high exposure to 
PM10 and NO2, and carrying out manual work (Papathomas et al 2011). This technique
considers the exposome as a whole instead of breaking up risks for individual exposures
and is therefore able to capture effects and complex interactions and combinations of
exposures that cannot be detected with the EWAS approach. 
SEMs and Bayesian profile regression models will also be used to account for the effects of
exposure measurement error and uncertainty, in addition to more classical measurement error 
models such as regression calibration. The general idea is that these techniques treat
exposures not as a fixed value but as a distribution, that can be informed from the repeated 
measurements (e.g. of non-persistent pollutants) and personal measurements (e.g. of air 
pollutants) in the panel studies. As a preliminary step, a simulation study aimed at comparing 
the efficiency of various study designs and statistical approaches to characterize the impact of
the exposome on health will be conducted. With a sample size of 1,200 (subcohort), the
agnostic EWAS analysis with control for FDR will have a power of 80% to detect a 3 point
difference in a continuous outcome variable with a standard deviation of 15 (as in common 
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neurodevelopment indexes), considering that 15% of the tested exposures will show an 
association (Liu and Hwang 2007). Higher power will be achieved for exposures available for 
more subjects (e.g. air pollution) and more hypothesis-driven analyses.  
Heterogeneity between cohorts in terms of study design can play a role in the results of these 
analyses, but it will not be possible to separate these effects from true differences between 
populations. We will address the issue of cohort differences in two ways: 1) by centering all 
exposures using the cohort mean. Analyses conducted with mean-centered variables will 
remove differences between cohorts and only consider within-cohort differences in exposure. 
2) by documenting heterogeneity between cohorts, applying random effects models where 
applicable, and conducting sensitivity analyses excluding one cohort at the time. 
Research Area 6 - Health Impact of Multiple Exposures 
Finally, research area 6 will estimate the burden of common childhood diseases that may be 
attributed to multiple environmental exposures in Europe. It will construct scenarios for the 
health impact assessment, working from traditional one-exposure-one-outcome assessments 
(e.g. traffic-related air pollution and asthma, mercury and neurodevelopment) to more 
complex benefit-harm scenarios. For example: given increasing obesity rates, children are 
encouraged to walk or cycle to school which may lead to increased energy expenditure and 
possible reduction in weight and improvement in mental health. However, at the same time, 
longer duration of exposure to air pollutants, noise and UV, may lead to adverse health 
effects and higher risks of accidents (Rojas-Rueda et al. 2012). Do the overall benefits 
outweigh these risks and what should policy makers do to improve these conditions of active 
transportation? This work will integrate exposure, uncertainty, and biomarker data obtained 
in HELIX, risk estimates obtained in HELIX, exposure-response data from the literature, 
exposure data from other existing birth and child cohorts (Vrijheid et al. 2012) and Europe-
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wide surveys, and prevalence data from existing health registries/surveys in Europe. Expert 
workshops will be organised to obtain information. 
Data Warehouse 
Data from the previous cohort follow-ups, the new follow-up at 6-9 years, the panel studies, 
and the omics and biomarker analyses, will be stored in a common, central database (data 
warehouse) with common, centrally established, QA/QC procedures. Mechanisms to transfer 
and hold data from across cohorts and other partners will include the identification of agreed 
data sets, specifications for the data warehouse, data validation, cleaning and harmonization 
procedures, and the establishment of robust data security mechanisms. Data analyses 
protocols will be established and performed centrally by a statistical analysis task force.  
Further, the data warehouse will be established in a format that will allow future uses beyond 
the project as an accessible resource for researchers external to the project. Procedures for 
external access will be developed and made public by the end of the project; this will include 
information regarding data collection, data content and procedures for data requests.  
Conclusions 
There is a strong consensus that new integrative tools and approaches for human exposure
and risk characterization are needed to significantly advance environmental risk and health 
impact assessment and health protection (Cohen Hubal et al. 2010; Lioy and Rappaport 2011;
NRC 2012). Specifically, new approaches are needed to measure and integrate a wide range
of (known and unknown) chemical and physical exposures from different sources and link 
these to health. The exposome concept may be a useful paradigm for this. HELIX is one of
the first attempts to describe the early-life Exposome of European populations and unravel its
relation to omics markers and health in childhood. As proof of concept, it will be able to 
evaluate the many challenges in the implementation of the exposome concept and it will form
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an important first step towards the description of the life-course exposome and its health 
effects
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Table 1. Individual exposures.
Exposure group Entire cohorts (N=32,000) HELIX subcohort (N=1200) Children panel study (1 week in
2 seasons) (N=150)
Pregnancy panel study (1 week in
2 seasons) (N=150)
PCB-153, DDE,
HCB, PBDE-47
- Biomarkers: in stored pregnancy blood samplesa 
and in newly collected child blood samples.
- -
PFAS (PFOS,
PFOA, PFBS,
PFHxS, PFNA)
- Biomarkers: in stored pregnancy blood samplesa 
and in newly collected child blood samples.
PBPK models for pregnancy and childhood.
-
Metals (Hg, Pb,
and TMS)
- Biomarkers: in stored pregnancy samplesa and in
newly collected child samples: blood (Pb), urine
(TMS), and hair (Hg).
- -
Phthalates (13
metabolites)
- Biomarkers: in stored pregnancy urine samplesb 
and in newly collected child urine samples (last
night and first morning void).
Biomarkers: in daily repeat urine
samples. Daily data on diet,
cosmetics. PBPK model for DEHP.
Biomarkers: in daily repeat urine
samples. Daily data on diet, 
cosmetics. PBPK model for DEHP.
Phenols (BPA,
parabens, TCS,
BP3)
Biomarkers: in stored pregnancy urine samplesb 
and in newly collected child urine samples (last
night and first morning void).
Biomarkers: in daily repeat urine
samples. Daily data on diet,
cosmetics.
Biomarkers: in daily repeat urine
samples over whole week. Daily data
on diet, cosmetics.
OP pesticides - Biomarkers: in stored pregnancy urine samplesb 
and in newly collected child urine samples (last
night and first morning void).
Biomarkers: in daily repeat urine 
samples in two seasons. Daily data
on diet and repellent use.
Biomarkers: in daily repeat urine
samples in two seasons. Daily data on
diet and repellent use.
Water DBPs Estimates available from
previous HiWATE project
during and after pregnancy.
New questionnaire in children on water
consumption and swimming combined with
water company data.
Water consumption diaries. Water consumption diaries.
Indoor air:
BTEX, NO2,
PM2.5 
Existing questionnaire data
on indoor sources during 
and after pregnancy.
New questionnaire in children on cooking,
heating, cleaning, and ventilation.
Passive BTEX and NO2 sampling in
the home. Active PM2.5 sampling.
Questionnaire on cooking, heating,
cleaning, and ventilation.
Passive BTEX and NO2 sampling in
the home. Active PM2.5 sampling.
Questionnaire on cooking, heating,
cleaning, and ventilation.
ETS Existing questionnaire and
cotinine data during and
after pregnancy
New questionnaire in children. Biomarkers:
cotinine measurement in newly collected child
urine and/or hair samples.
Questionnaire on ETS. Questionnaire on ETS.
aWhere measurements are available from previous studies these will be used. bPooling of 2 or more urine samples when available.
 
BP3: benzophenone-3; BPA: bisphenol A; BETX: Benzene, Toluene, Ethylbenzene, Xylene; DBPs: disinfection by-products; DDE: dichlorodiphenyldichloroethylene; DEHP: bis(2-
ethylhexyl) phthalate (di-2-ethylhexyl phthalate; ETS: environmental tobacco smoke; HCB: hexachlorobenzene; Hg: mercury; NO2: nitrogen dioxide; OP: organophospate pesticides;
 
Pb: lead; PBDE-47: polybrominated diphenyl ethers-47; PCB-153:polychlorinated biphenyl-153; PFAS: perfluoroalkyl substances; PFBS: perfluorobutanesulfonic acid; PFHxS: 

perfluorohexane sulfonic acid; PFNA: perfluorononanoic acid; PFOA: perfluorooctanoic acid; PFOS: perfluorooctane sulfonic acid; TCS: triclosan; TMS: total metal spectrum.
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Table 2. Outdoor exposures.
Exposure
group
Entire cohort (N=32,000) – for pre
and postnatal exposure periods
Subcohort (N=1,200) Children panel study (1 week in
2 seasons) (N=150)
Pregnancy panel Study (1 week in 
2 seasons) (N=150)
Ambient air
pollutants
LUR model for NO2, PM2.5. PM10, 
PMcoarse PM2.5 aborbance, PM
elemental analyses. Routine
monitoring and OMI satellite data for
temporal variability
LUR model for NO2, PM2.5. PM10, 
PMcoarse PM2.5 aborbance, PM
elemental analyses. Routine
monitoring and OMI satellite data for
temporal variability
Inhalation rates and mobility (GPS) 
data from smartphones. Personal
monitoring (24 hours) of PM2.5 (and
black carbon.
Inhalation rates and mobility (GPS) 
data from smartphones. Personal
monitoring (24 hours) of PM2.5 and
black carbon.
Noise Existing municipal noise maps to
obtain spatial estimates. Address-based 
modelling of noise at the most and 
least exposed facade
New questionnaires in children on
bedroom position, noise perception,
etc. Noise estimates based on maps
and questions.
Time-activity and mobility (GPS) data 
from smartphones.
Time-activity and mobility (GPS) data 
from smartphones.
UV Remote sensing (satellite) UV
radiation maps.
New questionnaires in children on
traveling, use of sunscreens, clothes, 
skin color. UV radiation estimates 
based on maps and questions.
Time-activity and mobility (GPS) data 
from smartphones and questionnaires.
Personal monitoring using electronic
UV dosimeters.
Time-activity and mobility (GPS) data 
from smartphones and questionnaires.
Personal monitoring using electronic
UV dosimeters.
Temperature Remote sensing (satellite) temperature
maps (from thermal infrared band) and
data from local meteorological stations
New questionnaires in children on
heating and air conditioning.
Temperature estimates based on maps
and questions.
Time-activity and mobility (GPS) data 
from smartphones and questionnaires.
Personal monitoring of temperature
using electronic dosimeters.
Time-activity and mobility (GPS) data 
from smartphones and questionnaires.
Personal monitoring of temperature
using electronic dosimeters.
Built
environment /
green spaces
Normalized Difference Vegetation
Index from satellite. Building density,
walkability score, accessibility, bike
lanes, etc, derived from GIS data.
New questionnaires in children on use
of green spaces, public spaces, active
transportation. 
Time-activity and mobility (GPS) data 
from smartphones and questionnaires.
Time-activity and mobility (GPS) data 
from smartphones and questionnaires.
LUR: Land use regression, NO2: Nitrogen dioxide, NOX: Nitrous oxides, PM2.5: mass concentration of particles less than 2.5 µm in size, PM10: mass concentration of particles less
than 10 µm in size, PM2.5 absorbance: measurement of the blackness of PM2.5filters; a proxy for elemental carbon, which is the dominant light absorbing substance, PMcoarse: mass
concentration of particles between 2.5 and 10 µm in size, GPS: Global Positioning System.
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Table 3. Omics analyses.a 
Omics technique Entire cohort 
(N=32,000)
Subcohort (N=1,200 mother-child pairs) Children panel study (1 week in 2 seasons) (N=150)b 
Metabolomics - Untargeted 1H NMR and semi-targeted UPLC-MS 
analysis in urine; targeted analysis in serum (using 
Biocrates Absolute IDQ p180 Kit) in newly collected 
child samples.
Further analysis of daily urine samples and  single
serum sample at the end of each week (in winter and 
summer season) to evaluate sources of variation and 
short-term exposure-omics associations.
Proteomics - Targeted analysis in newly collected child plasma
samples depending on results on analysis in children 
panel study.
Initial iTRAQ and MRM (or similar) analyses in 
plasma samples collected at end of each week (in 
winter and summer season) to evaluate sources of
variation and short-term exposure-omics associations.
Transcriptomics - Next generation sequencing (Ilumina Hiseq2000) or 
microarray analysis of both mRNAs and miRNAs in
newly collected child whole blood samples. In 
addition, plasma will be collected to analyse miRNAs
in the future.
Analysis of blood samples at end each week (in winter 
and summer season) to evaluate sources of variation 
and short-term exposure-omics associations. In 
addition, plasma will be collected to analyse miRNAs
in the future.
DNA methylation - Infinium Human Methylation 450 BeadChip for 
genome-wide methylation analysis of DNA extracted 
from newly collected child whole blood samples.
Analysis of blood samples at end each week (in winter 
and summer season) to evaluate sources of variation 
and short-term exposure-omics associations.
aDetails of the techniques are described in Supplemental Material, Detailed description of omics techniques to be used in HELIX. bThe pregnancy panel
study will collect similar biological samples to the children panel study. Omics analyses are currently not foreseen in the pregnant women, but samples
will be stored for future analysis, e.g. to evaluate if specific omics findings from the children studies are replicated in the pregnant women.
NMR: nuclear magnetic resonance; iTRAQ = Isobaric tags for relative and absolute quantitation; MRM: mass spectrometry-based multiple reaction 
monitoring, mRNA: messengerRNA, miRNA: microRNA, UPLC-MS:  ultra performance liquid chromatography–mass spectrometry. 
  
  
  
 
 
   
 
  
  
  
Figure Legends 
Figure 1. HELIX Conceptual Framework and interactions between research areas.

Figure 2. Participating birth cohorts.
 
Figure 3. Study design, study populations, data sources.
 
Figure 4. Time line of the omics analysis.
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